SPOTLIGHT: Regulators question anemia drugs

Concerned by new safety data, European regulators have initiated a review of anemia drugs made by Amgen and Roche and is cooperating with Johnson & Johnson on a review of Eprex. Anemia drugs command an $11 billion market but have recently come under a cloud. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.